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Serine Phosphorylation of Death Agonist BAD
in Response to Survival Factor Results
in Binding to 14-3-3 Not BCL-XL
Jiping Zha, Hisashi Harada, Elizabeth Yang, also comprised of positive and negative regulators of
cell death. The ratio of antagonists (Bcl-2, Bcl-xL, Mcl-1,Jennifer Jockel, and Stanley J. Korsmeyer
and A1) to agonists (Bax, Bak, Bcl-xS, and Bad) dictatesDivision of Molecular Oncology
whether a cell will respond to a proximal apoptotic stim-Departments of Medicine and Pathology
ulus (Oltvai and Korsmeyer, 1994). A family of ICE-likeHoward Hughes Medical Institute
cysteine proteases are also activated in apoptosis. Acti-Washington University School of Medicine
vated proteases cleave substrates at a novel P1 aspar-St. Louis, Missouri 63110
tic-acid site. Some of these may represent downstream
death substrates, which upon proteolytic cleavage en-
sure the inevitability of apoptosis (Martin and Green,Summary
1995). Genetic studies of C. elegans favor a sequence
in which an ICE-like gene, Ced-3, is downstream of itsExtracellular survival factors alter a cell’s susceptibil-
BCL-2 homolog, Ced-9 (Shaham and Horvitz, 1996).ity to apoptosis, often through posttranslationalmech-
Consistent with this, biochemical studies in mammaliananisms. However, no consistent relationship has been
cells demonstrated that CPP32, an ICE-like protease,established between such survival signals and the
is not activated when BCL-2 is present blocking theBCL-2 family, where the balance of death agonists
response to an apoptotic stimulus (Armstrong et al.,versus antagonists determines susceptibility. One dis-
1996; Chinnaiyan et al., 1996). In total, these studiestant member, BAD, heterodimerizes with BCL-XL or
argue that the BCL-2 family of proteins constitutes aBCL-2, neutralizing their protective effect and promot-
decisional point, clearly proximal to the irreversible dam-ing cell death. In the presence of survival factor IL-3,
age of cellular constituents.cells phosphorylated BAD on two serine residues em-
To date, most of the progress in understanding cellbedded in 14-3-3 consensus binding sites. Only the
death has been horizontal. The interacting molecules atnonphosphorylated BAD heterodimerized with BCL-XL the level of either the surface receptors, BCL-2 family,at membrane sites to promote cell death. Phosphory-
or ICE-like proteases have expanded. However, majorlated BAD was sequestered in the cytosol bound to
challenges remain in linking these steps to integrate14-3-3. Substitution of serine phosphorylation sites
this pathway vertically. Of particular relevance would befurther enhanced BAD’s death-promoting activity. The
insights into the mechanism by which survival factorsrapid phosphorylation of BAD following IL-3 connects
and the engagement of their receptors alter the setpointa proximal survivalsignal with theBCL-2 family, modu-
of susceptibility to apoptosis. Alterations of the BCL-2
lating this checkpoint for apoptosis.
proteins by survival signals would constitute an attrac-
tive candidate because studies of gain and loss of func-
Introduction tion implicate the BCL-2 family as a critical checkpoint
capable of preventing cell death (McDonnell et al., 1989;
The survival of cells in multicellular organisms requires Veis et al., 1993). Rare examples exist where exposure
continuous cues from theextracellular environment. Life to a cytokine alters a BCL-2 family member; for example,
or death decisions often depend on non-cell-autono- GM-CSF results in induction of A1 (Lin et al., 1993),
mous communication, which appears to be required to providing evidence that BCL-2 proteins can represent
maintain homeostasis (Raff, 1992). Tremendous prog- a site of regulation by survival factors. However, in most
ress has been made in identifying extracellular, cell sur- situations interrogated, there is little change in absolute
face, and intracellular molecules that regulate pro- levels of BCL-2 proteins. While expression of Bcl-2 will
grammed, apoptotic cell death. Intriguingly, positive and protect early hematopoietic cells from IL-3 withdrawal
negative regulators have been identified at each level. (Vaux et al., 1988; Nun˜ez et al., 1990), there are not
This includes a series of cytokines that often function substantial alterations of BCL-2 protein levels following
more as survival factors than growth factors (Metcalf, withdrawal or readdition of IL-3 in such cells (Cleveland
1989; Oppenheim, 1991; Raff, 1992). Conversely, other et al., 1994; Canman et al., 1995). A series of neuro-
ligands such as FasL specifically trigger apoptosis (Wa- trophic factors including NGF, BDNF, and NT-3 did not
tanabe-Fukunaga et al., 1992). One set of cell surface significantly alter BCL-2 protein levels in cells bearing
receptors, including FAS and TNFR-55, transduce sig- the appropriate receptor (D. Merry and S. J. K., unpub-
nals that activate a downstream, common apoptotic lished data). Moreover, IGF1, which functions almost
pathway (Itoh et al., 1991; Tartaglia et al., 1993; Smith exclusively as a survival factor, did not alter the levels
et al., 1994). In contrast, a balancing set of surface re- of assessed BCL-2 proteins in fibroblasts where it pro-
ceptors such as the TRKs, IL-3R, and IGFR transduce tected them from c-Myc-induced death in low serum.
signals that increase the resistance of cells to apoptosis Like most survival factors, IGF1 inhibits apoptosis in the
(Harrington et al., 1994; Bothwell, 1995; Kinoshita et al., absence of protein synthesis (Harrington et al., 1994).
1995). This indicates that much of the effect of survival factors
Beyond these proximal signals lie several critical, in- will be mediated through posttranslational mecha-
tracellular decision points within a common cell-death nisms.
pathway. The first of these is constituted by the Bcl-2 BAD, a very distant BCL2 family member, bears only
the universally conserved amino acids of the BH1 andfamily of proteins (Farrow and Brown, 1996), which is
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BH2 domains and represents one candidate for linking
signal transduction events to the BCL2 family. BAD ap-
parently exerts its death-promoting effects by hetero-
dimerizing with BCL-2 or BCL-XL death antagonists
(Yang et al., 1995). BAD does not homodimerize, lacks
the typical signal/anchor segment suggesting that its
free form may reside in the cytosol, and has PEST se-
quences and a much shorter half-life. These parameters
suggested that BAD could prove to be more proximal
at the BCL2 step perhaps linked to signal events. An
antibody generated to BAD revealed its migration as a
doublet, prompting the demonstration of its differential
phosphorylation on serine residues within 14-3-3 bind-
ing sites. Of note, phosphorylated BAD is complexed
with 14-3-3 in the cytosol while only the nonphosphory-
lated BAD is heterodimerized with BCL-XL at membrane
sites. The requisite survival factor for this cell, IL-3, re-
sults in the immediate phosphorylation of BAD, estab-
lishing a link between this extracellular factor and the
BCL2 checkpoint.
Results
BAD Interacts with 14-3-3 In Vivo
Expression cloning (Blanar and Rutter, 1992) was used
to screen for further proteins that interact with BAD,
beyond the known partners of BCL-XL and BCL-2. GST-
BAD fusion protein bearing a heart muscle kinase (HMK)
motif was labeled with [g-32P] ATP in vitro to screen an
oligo (dT)-primed mouse embryonic day 16 EXlox cDNA
expression library. Two independent clones of the tau
form (t) of 14-3-3 (Nielsen, 1991) were isolated. The pro-
tein sequence of this isolatedmurine gene provedequiv-
alent to a previously cloned human homolog (identical,
except an Asp143Glu substitution). Recently, 14-3-3 has
been demonstrated to be a specific phosphoserine-
binding protein (Muslin et al., 1996). Thus, phosphoryla- Figure 1. Coimmunoprecipitation of BAD and 14-3-3 in FL5.12 Cells
tion of a serine within the HMK motif could have medi-
(A) Western blot of lysates and 14-3-3 immunoprecipitates (IP) (anti-
ated the binding to 14-3-3. To exclude this possibility, HA, 12CA5 mAb) from FL5.12 Neo and FL5.12 HA14-3-3/Bad cells
we assessed whether a BAD/14-3-3 t interaction oc- developed with a biotinylated anti-BAD Ab (10929).
(B) Western blot of BAD immunoprecipitates (anti-BAD, 2G11 mAb)curred in vivo. Stably transfected clones of FL5.12, an
from FL5.12 Neo and FL5.12 HA14-3-3/Bad cells developed withIL-3 dependent hematopoietic cell line, coexpressing
the anti-HA mAb (12CA5).wild-type (wt) BAD and hemagglutinin (HA)-tagged 14-
(C) Immunoprecipitation of 35S-labeled FL5.12 Neo and FL5.123-3 t, were identified. Western analysis of cell lysates
HA14-3-3/Bad cells using the anti-BAD mAb (2G11). Arrows indicate
from such cells with an anti-BAD rabbit polyclonal Ab the position of HA14-3-3 t, endogenous 14-3-3, and BAD.
(10929) revealed that BAD migrated as a doublet of ap- (D) Western blot of lysate and BAD immunoprecipitates (anti-BAD,
2G11) from FL5.12 Neo and FL5.12 HA14-3-3/Bad cells developedproximately 24/25 kDa (Figure 1A). This doublet is also
with an anti-14-3-3 Ab (UBI). Arrows indicate the position of HA14-present in cells that express BAD but no HA14-3-3 (data
3-3 t and endogenous 14-3-3.not shown). Immunoprecipitation of HA14-3-3 with the
anti-HA mAb (12CA5) resulted in the coprecipitation of
both BAD species. because BAD interacts with endogenous 14-3-3 species
within FL5.12 cells as well.A hamster mAb specific for mouse BAD (2G11) was
prepared and utilized in a reciprocal immunoprecipita- The BAD/14-3-3 interaction suggested several possi-
ble functional roles. 14-3-3 has been shown to associatetion. This demonstrated that HA14-3-3 coprecipitated
with BAD (Figure 1B). When 35S-labeled FL5.12 HA14- with signaling proteins including RAF1, middle T anti-
gen, BCR, and PI-3 kinase (Fantl et al., 1994; Freed et3-3/Bad cells were immunoprecipitated with the 2G11
anti-BAD mAb, additional proteins of appropriate size al., 1994; Fu et al., 1994; Irie et al., 1994; Pallas et al.,
1994; Reutheret al., 1994; Bonnefoy-Berand et al., 1995).for endogenous 14-3-3 and HA14-3-3 were coprecipi-
tated (Figure 1C). Western blot analysis of this immuno- In particular, overexpression of 14-3-3 can enhance the
kinase activity of RAF1 (Freed et al., 1994; Irie et al.,precipitate with an anti-14-3-3 polyclonal Ab confirmed
their identity as 14-3-3 (Figure 1D). The 14-3-3 interac- 1994). However, the kinase activity of RAF1 within
FL5.12 cells was unaffected by the presence or absencetion does not appear to be restricted to the t isoform
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phosphorylated components. Phosphoamino-acid anal-
ysis of the BAD doublet revealed that BAD was exclu-
sively phosphorylated on serine residues (Figure 2C).
RSXSXP/RXRXXS Motifs Are
Phosphorylated in BAD
To identify the precise sites of serine phosphorylation,
we performed two-dimensional (2-D) tryptic peptide
maps of upper and lower BAD species. BAD was immu-
noprecipitated from [32P]orthophosphate-labeled cells,
separated by SDS–PAGE, transferred to a nitrocellulose
membrane, and digested with trypsin. The digested pep-
tides were either directly applied onto a thin-layer chro-
matography (TLC) plate or treated with performic acid
before application to the TLC plate. Peptides were sepa-
rated according to charge in the first dimension, fol-
lowed by hydrophobicity in the second dimension. The
2-D maps of the upper and lower BAD species were
identical (Figures 3A and 3B). Spots 1 and 2 were noted
to vary in their relative proportion between various prep-
arations. Performic-acid treatment resulted in the con-
Figure 2. In Vivo Phosphorylation of BAD on Serine version of spot 1 to spot 2 (Figures 3A and 3B), sug-
(A) Immunoprecipitation (IP) of BAD from 32P-labeled FL5.12 Bcl-xL/ gesting that both spots were derived from the same
Bad cells using an anti-BAD mAb (2G11). BAD within the total lysate peptide but were differentially oxidized in preparation.
of the same cell line was compared by Western blot using an anti-
The 32P-labeled tryptic peptides from all three spotsBAD Ab (10929).
were subjected to manual Edman degradation. The 32P-(B) Potato acid phosphatase (PAP) treatment of BAD. BAD was
labeled position of spot 1 or 2 was located at amino acidimmunoprecipitated from FL5.12 Bcl-xL/Bad cells and treated with
1.5 U of PAP at 378C for 30 min in the absence or presence of residue number 1 (Figure 3D), whereas it was located at
phosphatase inhibitors. amino acid residue number 3 for spot 3 (Figure 3F). BAD
(C) Phosphoamino acid analysis of BAD. BAD was immunoprecipi- possesses five tryptic peptides with serine at position
tated from 32P-labeled FL5.12 Bcl-xL/Bad cells, separated by SDS– 1, and three tryptic peptides with serine at position 3.PAGE, and transferred to nitrocellulose membrane. Both species of
Synthetic peptides with phosphoserine replacements atBAD were digested with trypsin and hydrolyzed with hydrochloric
the corresponding positions were generated, comi-acid. The amino acid composition was determinedby TLC. Encircled
areas represent the location of phosphoserine (Ser), phosphothreo- grated on TLC plates, and compared with the 32P-labeled
nine (Thr), and phosphotyrosine (Tyr) based on ninhydrin staining. peptides isolated from spots 1 and 3. This revealed
that spot 1 was a peptide with phosphorylated Ser-136
(Figures 3D and 3E), while spot 3 was a peptide with
phosphorylated Ser-112 (Figures 3F and 3G). The upperof BAD as assessed by phosphorylation of histone H1
band consistently displayed more 32P-cpm and a higherin vitro (data not shown). In addition, we utilized an in
specific activity. This suggests that the upward mobilityvivo reporter system of RAF1 function in yeast (Irie et
shift reflects simultaneous phosphorylation of bothal., 1994). In this system, we found that the introduction
sites, whereas the bottom band would only be phos-of BAD did not affect the activation of RAF1 by BMH1
phorylated on either site. Ser-112 and Ser-136 reside(a 14-3-3 homolog in yeast). Moreover, we were unable
within RXRXXS and overlap RSXSXP consensus motifsto detect RAF1 in the coprecipitate of BAD and 14-3-3.
(Figure 8A). Both motifs have been found at the 14-3-3Since RAF1 activity was not apparently modulated by
binding sites in other proteins (Muslin et al., 1996).BAD, we next examined whether BAD was a target of
A series of kinases was assessed in vitro to determinephosphorylation.
which would phosphorylate BAD protein purified from
a bacterial expression system. RAF1, PKC, and HMKBAD Is Phosphorylated on Serine In Vivo
could phosphorylate BAD in vitro (data not shown), butWhen BAD-expressing cells were labeled with [32P]or-
only HMK phosphorylated BAD at one of the correctthophosphate and immunoprecipitated with 2G11 mAb,
sites, Ser-112 (Figure 3C). HMK phosphorylation of thisboth bands of the BAD doublet proved to be phosphory-
serine residue in the GST-BAD probe may explain thelated (Figure 2A). However, compared to an immunoblot,
original isolation of 14-3-3 t by expression cloning.the upper band was hyperphosphorylated, while the
lower was hypophosphorylated. Treatment of immuno-
precipitated BAD with potato acid phosphatase (PAP) Survival Factor, IL-3, Results
in BAD Hyperphosphorylationeliminated the upper band, apparently converting it to
the lower species (Figure 2B). This argues that hyper- A posttranslational modification of BAD raised the pos-
sibility that this differential phosphorylation might bephosphorylation is responsible for the mobility shift of
BAD. The lack of a shift of the lower band following PAP intended to regulate its death-agonist activity. FL5.12
cells, including the FL5.12 Bcl-xL/Bad clones, depend ontreatment was the first suggestion that the lower band
could be comprised of unphosphorylated as well as IL-3 for their survival. Consequently, we tested whether
Cell
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Figure 3. RSXSXP/RXRXXS MotifsAre Phos-
phorylated in BAD
(A) 2-D map of tryptic peptides from in vivo
phosphorylated BAD. BAD was immunopre-
cipitated from 32P-labeled cells, size-fraction-
ated by SDS–PAGE, and transferred to a ni-
trocellulose membrane. The tryptic-digested
fragments were eluted from the membrane,
and peptides were separated by TLC ac-
cording to charge (horizontal axis) and hydro-
phobicity (vertical axis). The pattern of the
lower band of BAD is shown, but the upper
band was identical.
(B) 2-D map of tryptic peptides from in vivo
phosphorylated BAD treated with performic
acid to oxidize peptides uniformly. The arrow
denotes the conversion of spot 1 to spot 2
by performic acid. The pattern of the lower
band of BAD is shown, but the upper band
was similar.
(C) 2-D map of tryptic peptides from BAD
in vitro phosphorylated by HMK. Histidine-
tagged BAD was used as the substrate for
HMK. An HMK-phosphorylated tryptic frag-
ment corresponded to spot 3. This was con-
firmed by comigration of a synthetic peptide
bearing a phosphorylated Ser-112 (not
shown).
(D) Manual sequencing of spot 1/2 tryptic
peptide. The 32P-labeled peptide was eluted
from the TLC plate, conjugated to a Sequelon
AA membrane, and subjected to manual Ed-
man degradation. The 32P-cpm on the mem-
brane (open circle) and in the elution (solid
bar) were recorded during each cycle of se-
quencing.
(E) 2-D map of a cold synthetic peptide and the 32P-labeled peptide of spot 1. The in vivo 32P-labeled peptide of spot 1 was eluted from the
TLC plate, mixed with the synthetic tryptic peptide (SAPPNLWAAQR) with phosphoserine replacement at position 1, and subjected to mapping
analysis. The location of the 32P-labeled peptide or cold peptide was revealed by autoradiography or ninhydrin staining, respectively.
(F) Manual sequencing of spot 3 tryptic peptide. The procedure used (D) was followed.
(G) 2-D map of cold synthetic peptide and the 32P-labeled peptide of spot 3. The procedure used in (E) was followed. The sequence of the
synthetic peptide was HSSYPAGTEEDEGMEEELSPFR with phosphoserine replacement at position 3.
withdrawal and readdition of this survival factor would (Figure 4A, lanes 4 and 5). This was the case even in the
presence of IL-3 when the hyperphosphorylatedspeciesaffect BAD phosphorylation. Two hours following with-
drawal of IL-3, the hyperphosphorylated form of BAD was prominent. Western analysis of supernatants de-
pleted of BCL-XL complexes confirmed that the hyper-was almost eliminated (Figure 4A, lane 2), whereas 15
min after readdition of IL-3, the hyperphosphorylated phosphorylated, upper band resided there (Figure 4A,
lanes 6 and 7).BAD species becomes prominent (Figure 4A, lane 3).
This dynamic process could also be influenced by ki- Since BCL-XL is an integral membrane protein, pre-
dominantly localized to mitochondria (Gonzalez-Garcianase activators and inhibitors. Treatment with PMA in
the absence of IL-3 could shift BAD to the hyperphos- et al., 1994), we asked whether the phosphorylation sta-
tus of BAD also influenced its subcellular localization.phorylated form, while PMA also worked in conjunction
with IL-3 to promote hyperphosphorylation further (Fig- FL5.12 Bcl-xL/Bad cells were 35S-labeled and fraction-
ated into membrane and cytosolic fractions. The mem-ure 4B). In contrast, Staurosporine inhibited hyperphos-
phorylation of BAD, which normally follows readdition brane fraction possessed the lower band of 35S-labeled
BAD; while upper and lower bands were noted in theof IL-3. These data implicate a PMA-inducible, Stauro-
sporine-inhibitive kinase in the phosphorylation of BAD. cytosol (Figure 5A). 33P-labeling indicated that only non-
phosphorylated BAD was found in the membrane frac-However, since PKC did not correctly phosphorylate
BAD in vitro, another kinase may mediate this PMA tion; while thehypophosphorylated lower and the hyper-
phosphorylated upper bands resided in the cytosoleffect.
(Figure 5A). This observation further resolved the lower
band into hypophosphorylated BAD within the cytosolOnly Nonphosphorylated BAD Is Heterodimerized
with BCL-XL at Membrane Sites and nonphosphorylated BAD within the membrane
fraction.We next asked whether the phosphorylation status of
BAD affected its capacity to associate with the death These observations also suggested that BCL-XL might
differentially associate with only a portion of BAD in theantagonist BCL-XL. When BCL-XL was immunoprecipi-
tated, only the lower band of BAD was coprecipitated lower band. Immunoprecipitation of BCL-XL from FL5.12
Survival Factor Phosphorylates and Inactivates BAD
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Figure 4. Modulation of BAD Phosphorylation and Its Association
with BCL-XL
(A) IL-3 results in BAD hyperphosphorylation. IL-3 was withdrawn
from FL5.12 Bcl-xL/Bad cells for 2 hr (2IL-3), followed by readdition
of IL-3 for 15 min (1IL-3). BAD was detected in the total cell lysate,
the anti-BCL-XL immunoprecipitate (IP), and the supernatant follow-
ing depletion of BCL-XL complexes (IP sup) by Western blot using
a biotinylated anti-BAD Ab (10929).
(B) Modulation of BAD phosphorylation by kinase activators or inhib-
itors. FL5.12 Bcl-xL/Bad cells were examined after 2 hr of IL-3 depri-
vation (2IL-3) or 15 min following IL-3 readdition (1IL-3). IL-3 was
also readded with 10 nM or 1 mM Staurosporine (Stau) or 10 nM
phorbol myristate acetate (PMA) (IL-31PMA). PMA was also as-
sessed in the absence of IL-3 (PMA). BAD was detected by Western
blot using an anti-BAD Ab (10929).
Figure 5. BAD Phosphorylation Status Reflects Its Intracellular Lo-
calization and Its Association with Either BCL-XL or 14-3-3Bcl-xL/Bad cells confirmed that only a portion of immu-
(A) Intracellular localization of BAD and its phosphorylation status.nodetectable BAD protein associated with BCL-XL (Fig-
FL5.12 Bcl-xL/Bad cells were 35S-labeled or 33P-labeled and fraction-ure 5B, lanes 1 and 2). 32P-labeling established that this
ated into crude membrane (CM) and cytosol (Cyt) fractions. BADsubfraction was the nonphosphorylated portion of BAD
was immunoprecipitated with an anti-BAD Ab (10929) from both
(Figure 5B, lanes 1 and 3). A secondary immunoprecipi- fractions.
tation with anti-BAD Ab of the lysate depleted of BCL- (B) Coprecipitation of BAD species with BCL-XL. 32P-labeled FL5.12
Bcl-xL/Bad cells were immunoprecipitatedwith anti-BCL-X 7B2mAbXL revealed that the portion of BAD not associated with
(18 IP). The BCL-XL-depleted supernatant was subsequently immu-BCL-XL was comprised of hypo- and hyperphosphory-
noprecipitated with anti-BAD 2G11 mAb (28 IP). Within these immu-lated species (Figure 5B, lanes 2 and 4).
noprecipitates, BAD was detected by Western blot developed with
Finding phosphorylated BAD only in the cytosol but a biotinylated anti-BAD Ab (10929) or autoradiography.
not heterodimerized with BCL-XL at membrane sites (C) Coimmunoprecipitation of 14-3-3 and BAD. 32P-labeled FL5.12
could reflect several possible mechanisms. For exam- HA14-3-3/Bad cells were immunoprecipitated with anti-HA mAb
12CA5. Within these immunoprecipitates, BAD was detected byple, phosphorylated BAD might be sequestered in the
Western blot developed with a biotinylated anti-BAD Ab (10929) orcytosol by 14-3-3 and be unavailable for binding to BCL-
autoradiography.XL. Alternatively, phosphorylation of BAD might alter its
conformation and preclude its binding to BCL-XL. To
address this further, exogenous GST-BCL-XL protein Either Singly or Doubly Phosphorylated
was used to capture BAD from cell lysates, revealing Ser-112 and Ser-136 of BAD Binds
that only the lower species of BAD bound BCL-XL, while to 14-3-3 within the Cytosol
hyperphosphorylated BAD did not (Figure 6A). To deter- Upper and lower bands of BAD could be detected by
mine whether a hypophosphorylated species of BAD immunoblotting 14-3-3 complexes generated by immu-
would bind BCL-XL, bacterially expressed and purified noprecipitation with anti-HA (12CA5) Ab. The upper BAD
BAD protein was phosphorylated in vitro at Ser-112 by band is stronger (Figures 1A and 5C). Examination of
HMK. All nonphosphorylated BAD bound entirely to 32P-labeled cells confirmed that 14-3-3 interacts with the
GST-BCL-XL, whereas the phosphorylated BAD species hypo- and hyperphosphorylated forms of BAD (Figure
5C). To assess whether each RXRXXpSXP consensusdid not bind to BCL-XL (Figure 6B).
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14-3-3, demonstrated stronger death-agonist activity
than wt BAD. This was confirmed in a transient death
assay in which Bad or mutant Bad expression vectors
were transfected into Bad-deficient embryonic fibro-
blasts (data not shown). Moreover, each of the singly
substituted BAD112A or BAD136A clones was interme-
diate in activity between wt and doubly substituted BAD
(Figure 7C). We never detected a ternary complex
among BCL-XL, BAD, and 14-3-3 when immunoprecipi-
tates of BCL-XL or 14-3-3 were examined (data not
shown). This confirms that individual BAD molecules are
found with BCL-XL or 14-3-3, but not both. Thus, the
phosphorylation status of BAD appears to dictate its
subcellular localization as well as its capacity to associ-
ate with BCL-XL or 14-3-3 (Figure 8B).
Discussion
Apoptosis is governed by families of proteins with posi-
tive and negative regulatory members acting at serial
steps along a programmed pathway (Oltvai and Kors-
meyer, 1994). Recently, protein interactive cloning has
provided candidate molecules that could begin to link
these steps (Cleveland and Ihle, 1995). BAD is one such
molecule identified by its selective dimerization with
BCL-2 or BCL-XL. BAD is a death agonist that restoresFigure 6. Phosphorylated BAD Does Not Bind BCL-XL
apoptosis when bound to antagonists, BCL-2, or BCL-(A) Western blot detection of BAD species captured from cell lysates
by GST-BCL-XL fusion protein and that remaining in the supernatant XL (Yang et al., 1995). BAD proved to have cytosolic and
(sup) following depletion by GST-BCL-XL. Blot developed with an membrane-associated forms consistent with its lack of
anti-BAD Ab (10929). a COOH-terminal signal/anchor segment found in most
(B) Purified, bacterially expressed BAD protein was phosphorylated
BCL-2 family members. This first suggested that BADwith [32P]ATP in vitro by HMK (1HMK) or left untreated (2HMK).
might be involved in communicating transduced signalsEqual amounts of protein were incubated with GST-BCL-XL and
from the cytosol to the membrane-bound BCL-XL com-captured by GSH-agarose. The upper panel is Western blot detec-
tion of BAD bound to GST-BCL-XL or unbound in the supernatant plex. The phosphorylation of BAD following exposure to
(sup). The lower panel is an autoradiogram detecting distribution of IL-3 provides the first clear link between an extracellular
phosphorylated, 32P-labeled BAD. survival factor and altered susceptibility to apoptosis
due to a posttranslational modification of the BCL-2
checkpoint. Protein–protein interactionsbetween BCL-2site in BAD (Figure 8A) was capable of binding 14-3-3,
we generated Ser112Ala and Ser136Ala as well as Ser- family members determine, at least in part, the suscepti-
bility to cell death (Oltvai et al., 1993; Yang et al., 1995).112Ala and Ser136Ala double substitution mutants of
BAD. Several independent sets of FL5.12 Bcl-xL stable BAD is rapidly phosphorylated within 10 min of IL-3
exposure, consistent with prior observations that muchclones expressing comparable levels of wt BAD, BAD-
112A, BAD136A, or BAD112A136A were generated (Fig- of the effect of survival factors is via posttranslational
mechanisms. The phosphorylation of BAD results in itsure 7A). All BAD mutants still heterodimerized with BCL-
XL (data not shown). The upper mobility band of BAD binding to 14-3-3 in the cytosoland precludes its binding
to membrane-based BCL-XL, an event that enhanceswas only present with wt BAD, confirming that the upper
species was the result of doubly phosphorylated Ser- survival (Figure 8B). Since BAD phosphorylation deter-
mines its dimerization partners, this modification consti-112 plus Ser-136 (Figure 7A). Immunoprecipitation-
Western analysis revealed that RXRXXpSXP motif at tutes an attractive site for regulation by transduced sur-
vival signals.either Ser-112 or Ser-136 was independently capable
of binding 14-3-3. In contrast, the BAD112A136A double Phosphorylated BAD resides in the cytosol where it
is bound to 14-3-3. Both the doubly phosphorylated Ser-substitution did not bind 14-3-3, confirming that these
were the responsible phosphorylated serine sites for 112, Ser-136 BAD of the upper band, and either single
site–phosphorylated BAD of the lower band were com-this interaction (Figure 7B).
plexed with 14-3-3, which has been shown to be a motif-
specific phosphoserine binding protein. Ser-112 andSubstitution of Serine Phosphorylation
Sites Further Enhances BAD’s Ser-136 of BAD are homologous to the consensus bind-
ing motifs for 14-3-3 defined most critically for RAF1Death-Promoting Activity
FL5.12 Bcl-xL clones stably expressing comparable lev- (Figure 8A) (Muslin et al., 1996). Ser-136 of BAD has the
RSXSXP and overlapping RXRXXS motifs found in RAF1els of wt BAD or the various BAD mutants were deprived
of IL-3 and assessed for viability (Figure 7C). The non- at its 14-3-3 interaction site, whereasSer-112 only varies
at the 22 position (RHSSYP) of the RSXSXP motif. Thisphosphorylative BAD112A136A, which does not bind
Survival Factor Phosphorylates and Inactivates BAD
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Figure 7. Substitution of Serine Phosphorylation Sites in BAD Eliminates 14-3-3 Binding and Enhances BAD Death-Promoting Activity
(A) Western blot of lysates from FL5.12 Bcl-xL clones expressing wild-type (wt) BAD or alanine (A) substitutions for Ser-112, Ser-136, or both
developed with an anti-BAD Ab (10929).
(B) Western blot detection of 14-3-3 coimmunoprecipitated with BAD by anti-BAD mAb (2G11) from lysates of FL5.12 Bcl-xL clones expressing
wt or serine-substituted forms of BAD in Figure 7A developed with an anti-14-3-3 Ab (provided by Dr. Andrey Shaw, Washington University).
The arrow indicates the position of endogenous 14-3-3 detected in lysates of FL5.12 Bcl-xL/Bad cells.
(C) Viability of FL5.12 Bcl-xL clones expressing comparable levels of wt or serine-substituted BAD forms. Independent clones indicated by
the symbols were deprived of IL-3, and the fraction of viable cells was assessed by trypan blue exclusion. A second set of independent
clones, selected for comparable amounts of wt or mutant BAD proteins, confirmed these results.
histidine-for-serine substitution is also present in tyro- BCL-XL to reverse death protection. The most attractive
role for 14-3-3 based on our data would be as a chaper-sine hydroxylase (Furukawa et al., 1993), a known 14-
3-3 binding protein. Mutation analysis confirmed that one or protective binding protein for BAD that keeps it
sequestered in the cytosol. In addition, 14-3-3 mighteither phosphorylated site inBAD could mediate binding
with 14-3-3. Moreover, it appears that multiple 14-3-3 protect phosphorylated BAD from phosphatases, as
shown for 14-3-3/RAF1 associations (Dent et al., 1995).isoforms will bind BAD, consistent with the fact that
phosphorylated RAF1 peptides showed no 14-3-3 iso- The robust phosphorylation of BAD, upon distinct 14-
3-3 serine motifs following exposure to IL-3, has implica-form specificity. BAD lends further support to the role
of these phosphorylated serine motifs as distinct recog- tions for the responsible kinase. Several serine/threo-
nine kinases have been shown to phosphorylate 14-3-3nition sites for 14-3-3.
A ubiquitous and highly conserved protein, 14-3-3 is motifs in vitro, including Ca21 calmodulin-dependent
protein kinase Type II for tyrosine hydroxylase (Furu-essential in yeast and present as multiple isoforms in
mammals (Aitken, 1995). A wide array of functional roles kawa et al., 1993) and cyclic AMP-dependent protein
kinase (PKA) for RAF1 (Muslin et al., 1996). Phosphoryla-has been ascribed to 14-3-3. For example, 14-3-3 has
been shown to enhance the kinase activity of RAF1 tion of BAD in FL5.12 cells proved to be inducible by
PMA, and inhibited by Staurosporine. A number of ser-(Freed et al.,1994; Irie et al., 1994), a serine/threonine
kinase. However, BAD did not influence RAF1 activation ine/threonine kinases are induced following IL-3/IL-3
receptor engagement, providing an additional perspec-in yeast or mammalian cells. While RAF1 and BAD share
similar 14-3-3 binding motifs, we have not detected ter- tive. These include PKC, PIM-1, and the RAS/RAF/MAP
kinase pathway (Miyajima et al., 1993). Of these, an acti-nary complexes combining BAD, 14-3-3, and RAF1. Al-
ternatively, 14-3-3 might serve as a cofactor that BAD vated RAS pathway has been shown to confer a survival
advantage to hematopoietic cells (Cleveland et al., 1994;requires for its activity, analogous to the role of 14-
3-3 for exoenzyme S of Pseudomonas (Fu et al., 1993). Kinoshita et al., 1995). While PKC or RAF1 phosphory-
lated BAD on serine in vitro, the sites were not identicalHowever, the defined role for BAD is pro-apoptotic, in
which it is the nonphosphorylated species that binds to those identified in vivo. Of the kinases tested, HMK
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resulting in cell death (Yang et al., 1995). In contrast,
phosphorylated BAD would be inactive when held by
14-3-3 within the cytosol, freeing BCL-XL to promote
survival (Figure 8B). An alternative model, which cannot
be excluded currently, would hold that BAD is inactive
when bound by BCL-XL or 14-3-3. In that scenario, when
nonphosphorylated BAD exceeded available BCL-XL,
the released BAD would be a death agonist. Either way,
BAD is a critical molecule that communicates cues from
the extracellular environment through its phosphory-
lation.
A strong precedent exists for the importance of phos-
phorylation in regulating critical checkpoints where cel-
lular decisions must be coordinated with extracellular
cues. This includes the G1/S checkpoint of the cell cycle
in which the differential phosphorylation of RB dictates
whether E2F is released and cells progress into S phase
(Weinberg, 1995). The cyclin/CDK complexes that medi-
ate this phosphorylation are regulated by CDK inhibitors
that respond to external stimuli (Sherr and Roberts,
Figure 8. Dual Impact Model of IL-3 Induced Phosphorylation of 1995). Similarly, the phosphorylation of BAD is an attrac-
BAD
tive point where extracellular signals can alter the BCL-2
(A) The serine phosphorylation sites in BAD are compared with the
checkpoint governing cell-death decisions.14-3-3 binding motifs surrounding Ser-259 of RAF1. Overlapping
consensus motifs are denoted above and below the actual phos-
phorylated sequences in BAD or RAF1. Experimental Procedures
(B) Schematic representation inwhich phosphorylated BAD is bound
to 14-3-3 within the cytosol, while only nonphosphorylated BAD is The BAD antibodies used in this study include a rabbit polyclonal Ab
heterodimerized with membrane-bound BCL-XL. (10929) (Yang et al., 1995). We also generated a hamster monoclonal
antibody (mAb) (2G11) against murine full-length BAD. BCL-XL Abs
are a rabbit polyclonal Ab (13.6) and a murine mAb (7B2) against
human BCL-XL (Boise et al., 1995). Anti-b/z 14-3-3 Ab was from(a form of PKA) correctly phosphorylated BAD in vitro Upstate Biotechnology Inc. 12CA5 is a murine mAb recognizing the
at the Ser-112 site. 14-3-3 binding motifs represent a hemagglutinin of influenza virus.
reasonable PKA consensus site (Francis and Corbin, Phosphopeptides were synthesized by Quality Controlled Bio-
chemicals, Inc. (Hopkinton, MA). They were purified with high-pres-1994). While the candidate kinase might be membrane
sure liquid chromatography to 95% homogeneity. All peptides werebased, the differential phosphorylation and location of
shown to consist of a single species of the correct molecular weightBAD following survival factor may favor a cytosolic loca-
by mass spectrometry.
tion. Finally, the finding that single-site substitutions of
either Ser-112 or Ser-136 displayed slightly stronger
Plasmid Construction and Purification of GST-BAD
death-agonist activity than wt BAD (Figure 7C) suggests and Histidine-Tagged BAD Protein
that the responsible kinase/phosphatase(s) may be lim- Standardpolymerase chain reactions (PCRs) were used to construct
iting (Figure 8B). fusion plasmids. The HMK site (RRASV) was introduced between
the BamHI and EcoRI sites of pGEX-3X; Bad cDNA was cloned inPhosphorylation also appears to be involved in the
frame at the EcoRI site to create pGEX-3X-HMK-Bad. GST-BADregulation of BCL-2. BCL-2 is phosphorylated on serine
fusion protein was purified with GST agarose. pET-14b-Bad wasresidues in a hematopoietic cell line following exposure
constructed by cloning Bad cDNA into the BamHI site in frame with
to IL-3 (May et al., 1994). BCL-2 is also hyperphosphory- histidine-tagsequence. Histidine-tagged BADproteins were purified
lated on serine residues following treatment with Taxol according to instructions from Novagen. To substitute Ser-112
(Haldar et al., 1995). While BCL-2 has been reported to (TCG) for Ala-112 (GCG) or Ser-136 (TCG) for Ala-136 (GCG) in BAD,
a PCR-based site-directed mutagenesis kit (Stratagene) was used.coprecipitate with RAF1, RAF1 did not appear to induce
The expression plasmids for wt Bad and mutants referred to asphosphorylation of BCL-2 (Wang et al., 1994). To date,
Bad112A, Bad136A, and Bad112A136A wereconstructed by cloningthe precise sites of serine phosphorylation on BCL-2
Bad cDNA into the EcoRI site of pSSFV. pSSFV-HA14-3-3 t was
following either stimulus have not been reported, but constructed by incorporating the HA epitope at the 59 end of 14-
BCL-2 does not have classic 14-3-3 binding sites. More- 3-3 t, which was cloned into the EcoRI site of pSSFV.
over, the biologic rationale for BCL-2 phosphorylation
is not as clear as that for BAD, in that it is uncertain Expression Cloning
whether BCL-2 phosphorylation is activating or inacti- GST-BAD was labeled with HMK (Sigma) and used to screen a
mouse day 16 EXlox cDNA library (Novagen). The hybridization wasvating (May et al., 1994; Haldar et al., 1995).
carried out in 20 mM HEPES–KOH (pH 7.7), 75 mM KCl, 0.1 mMThe differential phosphorylation status of BAD at cyto-
EDTA, 2.5 mM MgCl2, 1% milk powder, 1 mM dithiothreitol andsolic versus membrane sites suggests a model in which
0.05% Nonidet P-40 (NP-40), according to the protocol of Blanar
the presence or absence of survival factors would alter and Rutter (1992).
the equilibrium between these two populations (Figure
8B). Current data favor a model in which nonphosphory- Transfections
lated BAD represents the active form bound to mem- FL5.12 cells were electroporated at 200 V and 900 mF and plated
out 48 hr later at limited dilution in media containing 2 mg/ml G418brane-associated BCL-XL, which would displace BAX,
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or 2 mg/ml Hygromycin B in 96-well microtiter plates. Single-cell Cold phosphoserine, phosphothreonine, and phosphotyrosine were
added to the sample, which were applied together onto a TLC plateoriginated clones were selected after 7–10 days.
and separated by electrophoresis utilizing an HTLE-7000 apparatus
(CBS, Del Mar, CA) with equal volume of pH 1.9 and pH 3.5 buffersWestern Blot Analysis
(Boyle et al., 1991). The location of phosphoamino acids was deter-Cells were lysed in 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton
mined by ninhydrin staining and autoradiography.containing aprotinin (0.15 U/ml), 20 mM leupeptin, and 1 mM phenyl-
For 2-D mapping, tryptic peptides were separated in the firstmethylsulfonyl fluoride. Lysates were separated by SDS–PAGE, and
dimension in pH 8.9 buffer (Boyle et al., 1991) by TLC utilizing antransferred to a nitrocellulose membrane. The membrane was first
HTLE-7000 apparatus. Electrophoresis was performed for 30 minblocked with 3% milk powder for 1 hr, followed by incubation with
at 1000 V at 48C. Separation in the second dimension was performedprimary and secondary Abs for 1 hr each, and finally developed with
by ascending chromotography in 37.5% n-butanol, 25% pyridine,enhanced chemiluminescence (Amersham). Ab10929 was used at
and 7.5% acetic acid for 10 hr. Autoradiography was used to visual-1:2000 dilution, biotinylated 10929 was used at 1:1000, 12CA5 mAb
ize 32P-phosphopeptides; cold phosphopeptides were visualizedsupernatant was used at 1:50, and anti-14-3-3 Ab was used at
with ninhydrin staining.1:1000. The secondary Abs were used at 1:2000 dilution.
Manual Sequencing of 32P-PhosphopeptidesMetabolic Labeling and Immunoprecipitation
The labeled peptides were eluted in pH 1.9 buffer from TLC plates,FL5.12 cells were labeled either in phosphate-free RPMI1640 media
conjugated to Sequelon-AA membrane (Perseptive Biosystem, Fra-with [32P]- or [33P]orthophosphate (1 mCi/106 cells) or in methionine-
mingham, MA) with methanol:water:triethylamine:phenylisothiocya-free RPMI1640 media with [35S]methionine (200 mCi/106 cells) for 4
nate (7:1:1:1) at 558C. Manual Edman degradation was performedhr. Cells were lysed either in 137 mM NaCl, 20 mM Tris (pH 8.0), 1.5
as previously described (Boyle et al., 1991; Luo et al., 1991).mM MgCl2, 1 mM EDTA, 50 mM NaF, 0.2%–0.5% NP-40 containing
aprotinin (0.15 U/ml), 20 mM leupeptin, and 1 mM phenylmethylsul-
Cellular Fractionationfonyl fluoride for coimmunoprecipitation, or in radioimmunopre-
FL5.12 Bcl-xL/Bad cells were washed with phosphate-buffered sa-cipitation assay buffer for direct immunoprecipitation. Lysates were
line twice, resuspended in Buffer A containing 10 mM Tris (pH 7.5),first cleared with protein A beads for 30 min, followed by incuba-
25 mM NaF, 5 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 0.15tion with Ab for 1.5 hr on ice. Finally, the Ab complexes were cap-
U/ml aprotinin, 20 mM leupeptin, and 1 mM phenylmethylsulfonyltured with protein A beads for 1 hr. The immunoprecipitate was
fluoride, incubated on ice for 15 min, and homogenized in a Douncewashed with 0.2% NP-40 lysis buffer, resuspended in loading buffer,
homogenizer with 50 strokes. Nucleiwere removed by centrifugationand separated by SDS–PAGE. The gels were treated with fluorogra-
at 500 g for 10 min. The supernatant was further centrifuged atphy and visualized by autoradiography or were transferred to a
315,000 g for 30 min to separate cytosol from crude membranes.nitrocellulose membrane for further immunoblot analysis.
For immunoprecipitation, the membrane fraction was solubilized in
1% SDS and centrifuged at 12,000 g for 5 min at room temperature.Phosphatase Treatment of BAD
The supernatant was diluted 1:10 in 1% triton, 100 mM NaCl inBAD was immunoprecipitated from 10 3 106 of FL5.12 Bcl-xL/Bad
Buffer A. The cytosol fraction was also diluted in the same buffercells. The protein A bead–BAD complexes were resuspended in 500
condition. Immunoprecipitation proceeded as described previouslyml of 40 mM PIPES (piperazine-N,N9-bis[2-thansulfonic acid]) buffer
using an anti-BAD Ab (10929).(pH 6.0) containing 1 mM dithiothreitol, aprotinin (0.15 U/ml), 20 mM
leupeptin, and 1 mM phenylmethylsulfonyl fluoride. After 1.5 U of
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